Continuing Medical Education

Pan Pacific Lymphoma Conference

Grand Hyatt Kauai Resort & Spa

Dates: to July 22, 2022

Hybrid

CME Accredited | ACCME, ACPE, ANCC

Essential Information

CME Credit: Accredited for 28 Category 1 CME Credits Related to Cancer, Pathology
Standard Full Conference Registration Fee: $1000
Location: Grand Hyatt Kauai Resort & Spa

Conference Details

The Pan Pacific Lymphoma Conference is one of the largest gatherings of clinicians and researchers specializing in the areas of lymphoma and transplantation. The 2022 event is your chance to explore vital information on clinical updates and research, meet key thought leaders, and exchange ideas with more than 500 members of the multidisciplinary lymphoma clinical team including oncologists, hematologists, pathologists, clinical scientists, nurse practitioners, physician assistants, nurses, and pharmacists.

Conference Objectives:

1. Discuss common strategies and treatments in the management of lymphoma involving infectious disease prophylaxis, situations for consideration of therapy dose reductions, transfusion pharmacotherapeutics, orphan drugs, and fertility preservation
2. Identify factors related to provider burnout and the impact of its circumstances on patients' and providers’ well-being
3. Describe the molecular insights of lymphomagenesis and the pathological pathway to diagnosis of difficult cases
4. Discuss how minimal residual disease and imaging technologies can be incorporated to assist in improving treatment response evaluations
5. Assess novel and future therapies for the initial treatment of classical Hodgkin lymphoma (cHL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), primary central nervous system (CNS) lymphoma, and peripheral T-cell lymphomas (PTCL)
6. Evaluate the diverse landscape of monoclonal gammopathies of significance and the intersection of plasma cell dyscrasias
7. Analyze clinical trial results concerning prognosis and transplant-eligibility criteria for patients with relapsed cHL, FL, marginal zone lymphoma (MZL), and primary refractory DLBCL
8. Differentiate approaches to treatment for relapsed DLBCL between the need for autologous transplantation versus CAR-T therapy
9. Explain the roles of the interprofessional health care team in the diagnosis, treatment, management, and support of lymphoma and hematologic malignancies

Register Here »